Quarterly ResultMay 12, 2026, 08:52 AM
Imunon Q1 Net Loss $4.2M; Substantial Doubt on Going Concern
AI Summary
Imunon, Inc. reported a net loss of $4.2 million for the first quarter of 2026, an increase from $4.1 million in the prior year. The company's cash and cash equivalents significantly decreased to $4.8 million by March 31, 2026, with $4.0 million used in operating activities during the quarter. Management has identified substantial doubt about the company's ability to continue as a going concern, citing a need for additional capital funding, partnerships, and cost reductions.
Key Highlights
- Imunon reported a net loss of $4.2 million for Q1 2026, up from $4.1 million in Q1 2025.
- Cash and cash equivalents decreased to $4.8 million as of March 31, 2026.
- Net cash used in operating activities increased to $4.0 million for Q1 2026.
- Total stockholders' equity decreased to $3.4 million from $7.1 million at year-end 2025.
- Research and development expenses rose to $2.3 million in Q1 2026.
- Net loss per common share improved to $(0.84) in Q1 2026 from $(3.15) in Q1 2025.
- Management expressed substantial doubt about the company's ability to continue as a going concern.